Johnson & Johnson

09/13/2021 | Press release | Distributed by Public on 09/13/2021 06:49

ERLEADA® (apalutamide) Oral Presentations Demonstrate Importance of Prostate Specific Antigen (PSA) as Key Efficacy Indicator and Show Strong Patient Adherence Rates